USD 10.32 Billion
Report ID:
SQMIG35H2232 |
Region:
Global |
Published Date: June, 2024
Pages:
219
|Tables:
150
|Figures:
78
Circulating Tumor Cell Market size was valued at USD 11.38 Billion in 2023 and is poised to grow from USD 12.55 Billion in 2024 to USD 27.51 Billion by 2032, growing at a CAGR of 10.3% during the forecast period (2025-2032).
The global Circulating Tumor Cell (CTC) market provides promising marketplace dynamics formed by means of advancements in most cancers diagnostics. The growing occurrence of most cancers fuels demand for non-invasive diagnostic gear like CTC evaluation. Key drivers include the growing emphasis on personalised medicinal drug and the need for early most cancers detection. However, challenges such as technological complexity and the want for standardization avert massive adoption. ELISA and PCR-based totally strategies dominate product sorts. North America holds a tremendous market share due to well-established healthcare infrastructure. The market is characterized through ongoing research, collaborations, and product innovations to address evolving medical wishes.
Global Market Size
USD 10.32 Billion
Largest Segment
Clinical Liquid Biopsy
Fastest Growth
Clinical Liquid Biopsy
Growth Rate
10.3% CAGR
To get more reports on the above market click here to Buy The Report
The global circulating tumor cell market is segmented into product, specimen, technology, application, end user, and region. Based on product, the market is segmented into Kits & Reagents, Blood Collection Tubes, Devices or Systems. Based on specimen, the market is segmented into Blood, Bone Marrow, other body fluid. Based on technology, the market is segmented into CTC Detection (Immunocapture, Size-based separation, Density Based Separation, Combined Methods), CTC Detection method (SERS, Microscopy, Others), CTC Analysis. Based on application, the market is segmented into Clinical Liquid Biopsy (Risk Assessment, Screening and Monitoring), Research (Cancer Stem Cell, Drug Therapy Development). Based on end user, the market is segmented into Hospitals & Clinics, Research & Academic Institutes, Diagnostic Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
Analysis by Technology Type
CTC Enrichment is expected to dominate the market. Enrichment strategies, which includes nice and bad choice, filtration, and immunocapture, are pivotal in setting apart CTCs from blood samples. The versatility and efficiency of enrichment technologies in capturing uncommon circulating tumor cells make contributions to their substantial adoption, making them the dominant generation in the Circulating Tumor Cell marketplace.
Microchips are expected to be the quickest-growing era within the Circulating Tumor Cell marketplace. Microchip-based totally CTC detection leverages microfluidic structures to isolate and examine CTCs efficiently. The increasing demand for high-throughput, specific, and label-loose CTC evaluation drives the boom of the microchip era. Its potential to provide real-time records and enable single-mobile evaluation positions microchips as a rapidly evolving and modern era inside the CTC market.
Analysis by Application
The Cancer Detection utility phase is anticipated to dominate the Circulating Tumor Cell (CTC) market. Early cancer detection is a vital element in improving patient consequences, and CTC evaluation performs a critical position in figuring out and tracking cancer at an early stage. The Cancer Detection phase, encompassing numerous cancer kinds, is possibly to have significant adoption due to the growing emphasis on timely analysis for powerful treatment techniques.
The Monitoring and Prognosis utility segment is anticipated to be the fastest-growing. Continuous monitoring of CTCs gives valuable records for sickness progression and treatment reaction. As personalised medicinal drug gains prominence, the Monitoring and Prognosis segment is predicted to witness fast growth. It lets in clinicians to tailor treatment options primarily based on real-time facts, contributing to extra powerful and customized cancer control.
To get detailed analysis on other segments, Request For Free Sample Report
North America is poised to dominate the Circulating Tumor Cell (CTC) market. This dominance can be attributed to the location's advanced healthcare infrastructure, widespread research and development activities, and excessive prevalence of most cancer cases. Robust assist from healthcare establishments and a nicely-hooked up regulatory framework contribute to the sizeable adoption of CTC technologies, positioning North America as a leader in the market.
Asia-Pacific is expected to be the quickest-developing place in the CTC marketplace. Factors which include the growing occurrence of most cancers, growing consciousness of the approximately advanced diagnostic era, and huge healthcare investments make contributions to the area's increase. Additionally, efforts to enhance healthcare accessibility and affordability in nations like China and India are anticipated to pressure the adoption of CTC era for most cancers analysis and tracking, making Asia-Pacific a key player within the market's fast growth.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Drivers
Increasing Incidence Of Cancer Worldwide
Restraints
High Technological Complexity And The Need For Standardization
Request Free Customization of this report to help us to meet your business objectives.
The competitive environment of the Circulating Tumor Cell market is dynamic and characterised by using the presence of key industry players actively shaping the market dynamics. Companies play pivotal roles, conducting strategic tasks to maintain and decorate their market positions. Ongoing studies and development activities focused on technological advancements and the creation of innovative CTC analysis answers are well-known.
Top Player’s Company Profiles
Recent Developments
In March 2024, Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration.
In January 2024, Veracyte announced that it has reached a definitive agreement to acquire C2i Genomics, expanding its diagnostics platform to include whole-genome minimal residual disease (MRD) detection capabilities from cell-free DNA (cfDNA) in liquid biopsies. The MRD testing that C2i offers uses artificial intelligence (AI) to create circulating tumor DNA signatures by comparing the genomics of the patient’s tumor and blood, disposing of the need for bespoke biomarker panels.
In January 2024, Allogene Therapeutics Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products, and Foresight Diagnostics, the leader in the development of ultra-sensitive liquid biopsy circulating tumor DNA (ctDNA) detection announced a strategic partnership to develop a minimal residual disease (MRD) in-vitro diagnostic (IVD) to determine eligibility in ALPHA3, the first pivotal trial for first line (1L) consolidation treatment of large B-cell lymphoma (LBCL).
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
Global Circulating Tumor Cell marketplace evaluation exhibits a dynamic marketplace with a number of standout traits and problems. The marketplace is driven by using the rising international cancer prevalence, increasing demand for non-invasive diagnostic equipment, and improvements in CTC enrichment and detection technology. However, challenges include the complexity of CTC evaluation and the want for standardization. Enrichment technologies dominate the product panorama, with North America main regionally because of advanced healthcare infrastructure. Key traits include the mixing of CTC evaluation into recurring scientific practice and ongoing research in microfluidic structures. Collaborations and innovations underline the aggressive panorama, reflecting a trend closer to precision diagnostics in most cancers.
Report Metric | Details |
---|---|
Market size value in 2022 | USD 10.32 Billion |
Market size value in 2031 | USD 24.94 Billion |
Growth Rate | 10.3% |
Base year | 2023 |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Circulating Tumor Cell Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Circulating Tumor Cell Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Circulating Tumor Cell Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Circulating Tumor Cell Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35H2232
sales@skyquestt.com
USA +1 351-333-4748